DUBLIN--(BUSINESS WIRE)--The "Sodium Dependent Glucose Transporter 1 (SGLT1) Inhibitor - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering. Sodium Dependent ...
New findings reveal sotagliflozin's benefits for patients with heart failure with preserved ejection fraction without ...
Lexicon Pharmaceuticals targets a turnaround with sotagliflozin, LX9851, pilavapadin, and partnerships offering multiple ...
Sodium-glucose co-transporter 2 (SGLT2) inhibitors, initially developed to treat type 2 diabetes, have significant heart- and ...
News-Medical.Net on MSN
Preclinical evidence supports sotagliflozin's superior efficacy in attenuating salt-induced kidney damage
Sodium-glucose co-transporter 2 (SGLT2) inhibitors, initially developed to treat type 2 diabetes, have significant heart- and ...
Earlier this year, empagliflozin (Jardiance) won FDA approval for a broader indication in heart failure across the spectrum of ejection fraction. As part of our review of the year's top stories, we ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback